Treprostinil Iontophoresis in Diabetic Foot Ulcers

NewsBot · Dec 1, 2025

Members do not see these Ads. Sign Up.
Treprostinil Iontophoresis in Diabetic Foot Ulcers: A Single Ascending Dose Safety Study
Alicia Guigui et al
Fundam Clin Pharmacol. 2025 Dec;39(6):e70054.

Background: Diabetic foot ulcers (DFUs) represent a serious public health problem associated with significant morbidity and health costs. Despite optimal etiologic treatment and local care, amputation is frequent, stressing the need for new treatments. The benefit of systemic administration of vasodilators, such as prostacyclin analogues, has proven efficacy in other types of skin ulcers, but it is counterbalanced by potentially serious vasodilation-induced, concentration-dependent, adverse effects. Experimental data has shown the feasibility of local administration of treprostinil on the wound using iontophoresis.

Objective: We aimed to assess the safety of the local iontophoretic administration of treprostinil in patients with DFU through a single ascending dose safety study.

Methods: We conducted a prospective single ascending dose phase I study. Patients received a single dose of treprostinil applied via iontophoresis at a current density of 0.2 mA/cm2 for 30 min. Local and systemic adverse effects were monitored, and plasma treprostinil concentrations were measured over an 8-h follow-up period.

Results: Four patients were included, and received single doses of 0.025, 0.05, 0.1, and 0.25 mg/L at 0.2 mA/cm2 during 30 min, and were followed-up for 8 h. All patients did not present any significant adverse effect. Plasma concentration was below < 1.8 ng/mL 8 h after the administration.

Conclusions: Our results suggest that iontophoresis of treprostinil is a safe procedure at 0.25 mg/mL, without systemic adverse effect, suggesting its potential as a targeted treatment for DFUs.
Click to expand...

NewsBot · Dec 1, 2025

From ChatGPT:

Treprostinil is a medication used to treat pulmonary arterial hypertension (PAH) — a condition where the blood pressure in the arteries of the lungs is abnormally high, making it hard for the heart to pump blood through them.
Here’s a clear breakdown:
What Treprostinil Does

Treprostinil works by relaxing and widening the blood vessels in your lungs (vasodilation). This helps:

Lower pulmonary blood pressure

Improve blood flow

Reduce strain on the right side of the heart

Increase exercise capacity

Slow the progression of PAH symptoms

It acts as a prostacyclin analog, meaning it mimics the natural prostacyclin your body makes to keep blood vessels open and prevent clotting.
Forms of Treprostinil

Treprostinil comes in several delivery methods:

Injection (continuous IV or subcutaneous infusion — brand: Remodulin)

Inhaled (brand: Tyvaso)

Oral tablets (brand: Orenitram)

Different forms are chosen depending on severity, patient preference, and physician recommendations.
Common Side Effects

The most frequent ones differ by dosage form but generally include:

Headache

Flushing

Jaw pain

Diarrhea or nausea

Cough (inhaled form)

Infusion-site pain (for the subcutaneous pump)

Who Uses Treprostinil

Doctors prescribe it for WHO Group 1 PAH, often in patients who:

Need prostacyclin pathway therapy

Don’t respond fully to other PAH medications

Have moderate to severe symptoms

Treprostinil Iontophoresis in Diabetic Foot Ulcers

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Iontophoresis for hyperhidrosis

Low-Dye taping and iontophoresis for plantar fasciitis

Share This Page

Treprostinil Iontophoresis in Diabetic Foot Ulcers

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Iontophoresis for hyperhidrosis

Low-Dye taping and iontophoresis for plantar fasciitis

Share This Page

Useful Searches